Myocardial Infarction: Causes, Symptoms, and Emergency Response

Abstract

A heart attack, known medically as myocardial infarction, is essentially a serious manifestation of coronary artery disease that leads to myocardial damage or necrosis due to continuous ischemia. Major risk factors are hypertension, atherosclerosis, diabetes mellitus, hyperlipidemia, smoking, physical inactivity, and obesity. One must identify its symptoms for quick intervention, including chest pain, shortness of breath, profuse sweating, and nausea. High-sensitivity troponin assays, coronary angiography, percutaneous coronary intervention (PCI), and pharmacological interventions such as antiplatelet agents, beta-blockers, and statins have immensely improved patient outcomes due to advances in diagnosis and treatment. Reducing MI morbidity and mortality is critical in the early diagnosis, immediate intervention, and ongoing management.

Introduction

The most dangerous type of coronary heart disease is myocardial infarction, which arises from either acute or chronic myocardial ischemia brought on by an imbalance between oxygen supply and demand. An increase in cardiac biomarkers and clinical evidence that correlates with changes in ECG indicates myocardial injury or necrosis. Imaging can show acute abnormalities in regional wall motion or new damage to viable myocardium (1). Severe and ongoing chest pain is one of the clinical signs of myocardial infarction; it frequently coexists with dyspnea, nausea, and sweating. Angina, ischemic episodes, acute to severe arrhythmias, which can be life-threatening, and congestive heart failure are all possible outcomes of myocardial infarction. Therefore, depending on the kind and severity of the infarction, aggressive therapy should be started in the case of clinical doubt regarding myocardial infarction. Using supportive care and secondary prevention strategies is also crucial. The primary factors influencing the prognosis are the severity of the clinical symptoms, coexisting diseases, and the patient's reaction to the first round of treatment (2).

Definition

A myocardial infarction, commonly referred to as a heart attack, is defined pathologically as "myocardial cell death due to prolonged ischemia." The first ultrastructural changes are reduced cellular glycogen, sarcolemma disruption, and loosened myofibrils; abnormal mitochondria follow. The clinical definition of myocardial infarction is the presence of acute myocardial ischemia accompanied by immediate myocardial damage, as shown by abnormal cardiac biomarkers. (3)

Epidemiology

Analyzing epidemiology Myocardial infarction is the primary cause of cardiovascular disease (CVD)-related death worldwide. In 2016, 17.9 million deaths worldwide, or 31% of all deaths, were related to CVD. It is estimated that 2,36,000,000 people will pass away from CVD by 2030. Over 75% of deaths from CVD happened in poorer nations. Eighty-two percent of these deaths from CVD happened in low- and middle-income nations (5). The South Asian nations of Bangladesh, Sri Lanka, India, Pakistan, and Nepal have the highest rates of cardiovascular disease. adults over 75 are more likely than younger adults under 45 to get an age-specific myocardial infarction in developed countries. The opposite is true, too, in South Asian nations, where older adults over 60 are less likely than younger adults under 45 to experience an age-specific myocardial infarction (4).

The importance of MI is based on its influence on society and individual health. The World Health Organization (WHO) reports that, globally, MI and other cardiovascular diseases come first in causing death: they lead to 17.9 million annual fatalities. In the USA alone, every year, as many as 805000 people suffer from myocardial infarction, including more than 605 000 individuals who have experienced heart attacks for the first time ever. Meningococcal Inflammation is not only effective in making people sick and making people die, but it is also expensive in so far as society and medical care are concerned (4).

This is a review for people interested in learning about heart attacks. We will look at their signs, causes, and what to do when they occur. Myocardial infarction is the clinical term for a heart attack, which is a life-threatening condition that requires urgent attention. This article will help

you understand more about this disorder by using information from different sources, including research articles and medical facts.

Causes of Myocardial Infarction

Atherosclerosis and plaque rupture

A condition leading to the accumulation of cellular debris, inflammatory cells, and cholesterol and fatty deposits in the walls of arteries called atherosclerosis. Atherosclerotic plaques are its outcome (8). Plaques of this sort, being more prone to bursting than others due to instability, increase early rupture risks of coronary arteries, resulting in myocardial ischemia or infarction (7).MI, alongside related cardiovascular ailments, emerges among the biggest causes of death according to the World Health Organization, which says they account for 17.9 million deaths every year on a global scale. Atherosclerosis-related events, including MI and stroke, cause most cardiovascular mortality, emphasizing the importance of atherosclerosis in cardiovascular morbidity and mortality.

Acute myocardial infarction (AMI) results from the abrupt blockage of an artery when a plaque ruptures, thus initiating coronary thrombosis. Unstable plaques that contain a large lipid core, an infiltration of inflammatory cells, and a thin fibrous cap are particularly at risk. Acute coronary obstruction occurs when atherosclerotic plaques break down, leading to thrombus formation, blood contact, and platelet activation (Stoney, 9).

Risk factors

Non-modifiable Risk Factors

Age

Those who are older have a larger chance of dying from an acute myocardial infarction (10). It's still unknown what process causes the noticeable increase in mortality that comes with age (11). People 65 years of age or older account for 80% of heart disease deaths.[25]

Gender

Gender influences the risk of MI, with males experiencing heart attacks at a higher rate than premenopausal women. However, women's risk increases significantly at menopause, partly due

to altered hormone levels and diminished cardioprotective effects of estrogen (16). Women are more likely than men to get MI later in age if they experience atypical symptoms, which might delay identification and treatment (17).

Family History

A family history of premature coronary artery disease (CAD) or MI majorly predicts the likelihood of myocardial infarction (MI). In those individuals whose parent, sibling, or any other close relative had a heart attack before reaching 55 for males and 65 for women, the chances of developing CAD increase (18). This means that bad lifestyle preferences like diet are one factor affecting several family members and their offspring, although they might not be related by blood.

Modifiable Risk Factors

Hypertension

High blood pressure is one well-established modifiable risk factor for MI (19). According to the Centers for Disease Control and Prevention (CDC), about 45% of Americans have hypertension, which raises their risk of MI. In addition to increasing the strain on the heart, hypertension causes atherosclerosis, which causes arterial stiffness, endothelial dysfunction, and a higher risk of MI (12)(15).

Hyperlipidemia

Elevated cholesterol, especially low-density lipoprotein cholesterol (LDL-C), is linked to a higher risk of atherosclerosis and MI. Dyslipidemia raises a person's risk of MI because it encourages the development of atherosclerotic plaques in the coronary arteries (20). It is usual practice to lower LDL-C levels and lower the risk of cardiovascular events with statin medication (15).

Diabetes

Diabetes mellitus of any form, including type 1, significantly increases the risk of MI. Chronic hyperglycemia accelerates atherosclerosis, oxidative stress, inflammation, and endothelial dysfunction, all of which contribute to the development of CAD and MI. According to the International Diabetes Federation, those with diabetes have a two—to three-times higher risk of MI than those without the condition (21).

Smoking

Smoking is one of the primary modifiable risk factors for MI because it damages the heart. Tobacco smoke contains several toxic compounds that raise the risk of MI by encouraging inflammation, atherosclerosis, endothelial dysfunction, and platelet aggregation (22). The World Health Organization reports that tobacco use kills over 8 million people worldwide and that smoking is the primary cause of MI (14).

Obesity

Obesity is a body mass index (BMI) of 30 kg/m2 or greater, associated with an increased risk of MI. Atherosclerosis and MI are risks that are increased by obesity (23). In addition, it results in insulin resistance, dyslipidemia, metabolic issues, and systemic inflammation. According to the National Health and Nutrition Examination Survey, obesity has spread like wildfire and is having a catastrophic impact on cardiovascular health worldwide (13).

Sedentary Lifestyle

Physical inactivity is a modifiable risk factor for MI, independent of other risk factors, including obesity and high blood pressure. In addition to other cardiovascular benefits, regular exercise enhances lipid profiles, blood pressure regulation, endothelial function, and weight management (24). Sedentary behavior, on the other hand, has been connected to an increased risk of MI and other cardiovascular events. According to estimates from the World Health Organization, insufficient physical activity results in 3.2 million deaths annually throughout the globe (14).

Role of inflammation and endothelial dysfunction

Chronic inflammation plays a crucial role in the development of atherosclerosis, the primary cause of most myocardial infarctions (MIs). In response to endothelial injury, circulating monocytes migrate into artery walls to form foam cells, which release inflammatory mediators and hasten the formation and spread of plaque (25). Moreover, inflammation causes plaques to become unstable, which raises the possibility that they may burst and that an acute coronary event, like MI, would follow. Intravascular imaging studies have demonstrated the presence of inflammatory cells in the responsible lesions, shedding light on inflammation in plaque susceptibility and rupture (26).

Endothelial dysfunction, a key feature of atherosclerosis associated with increased arterial permeability, a prothrombotic state, and diminished vasodilation, is common between MI and atherosclerosis (27). Increased vascular tone and inadequate vasodilatory action from reduced

nitric oxide (NO) bioavailability in injured endothelium raise the risk of hypertension and coronary artery spasm. Defective endothelium also promotes a pro-thrombotic phenotype, characterized by increased production of adhesion molecules, tissue factors, and platelet activators. In regions with plaque erosion or rupture, there is an increase in platelet aggregation and thrombus formation (28).

Numerous epidemiological studies have demonstrated the link between the risk of MI and inflammatory biomarkers, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP). Elevated inflammatory marker levels, unaffected by conventional risk factors, can predict the onset of CAD and unfavorable cardiovascular events, such as MI (29).

Symptoms of Myocardial Infarction

Atypical symptoms

Shortness of breath

Dyspnea is one symptom of myocardial infarction that may appear even in the absence of the usual chest pain. Dyspnea or rapid, shallow breathing are common symptoms in patients (36). A myocardial infarction (MI) may be indicated by dyspnea due to diminished cardiac output or pulmonary congestion from left ventricular dysfunction (30). Respiratory conditions, including chronic obstructive lung disease and congestive heart failure, are frequently associated with dyspnea (35).

Research shows that shortness of breath (dyspnea) is typically the first indicator of a heart attack in old people, the elderly, and those who are affected by heart or lung complications simultaneously. The American Journal of Cardiology has reported that as many as 40% of individuals suffering from acute coronary syndrome show dyspnea as their primary symptom. Therefore, this justifies the need to consider dyspnea when evaluating possible MI patients (32).

Nausea and Vomiting

After a heart attack, nausea and vomiting can happen, especially among women and elderly persons. A person can feel nausea, vomit, or be sick to his/her stomach. These stomach-related

signs may be linked to an activation of the autonomic nervous system or a referral of interior discomfort caused by cardiac ischemia (37).

Studies reveal that nausea and vomiting are more common among older women with MI. Women were more predisposed than men to develop atypical symptoms such as nausea, vomiting, or back pain following acute coronary episodes, based on the JAMA Internal Medicine publication. At the same time, research published in the American Journal of Medicine found that older people with MI complain more often of gastrointestinal problems (31).

Diaphoresis

Sweating too much is known as diaphoresis, and it may tell us someone is at risk of having a heart attack when the sympathetic nervous system becomes active because it does not get enough oxygenated blood (38). Sometimes, even under the usual weather changes, normal people feel cold or hot and sweat more than usual. Excessive perspiration may indicate other symptoms of this disease, such as chest tightness or shortness of breath (34).

Studies show that diaphoresis is a very prevalent symptom in 20–30% of MI patients (33). According to research published in the American Journal of Emergency Medicine, diaphoresis was more common in patients with ST-segment elevation myocardial infarction (STEMI) than in those without it. This finding raises the possibility that diaphoresis is an indication of more severe ischemia.

Gender differences in symptomatology

Though men and women react to acute cardiac events differently, chest discomfort is the most typical indication of myocardial infarction in both sexes. Compared to men, women are more likely to experience odd symptoms rather than merely typical chest discomfort. These symptoms include dyspnea, tiredness, nausea, and vomiting. Research indicates that women are less likely than males to recognize or think that their symptoms are due to heart ischemia; as a result, they delay seeking medical attention and receiving a diagnosis (32).

Women were less likely than men to report chest pain as their main symptom during acute coronary syndromes, with 43% of women reporting atypical symptoms compared to 31% of males, according to research published in Circulation: Cardiovascular Quality and Outcomes. Women also tended to present with symptoms other than chest pain, which made identification more difficult and prolonged the start of therapy (33).

Emergency Response to Myocardial Infarction

Recognizing symptoms and activating emergency medical services (EMS)

For the best results and fastest care, it's imperative to identify the signs of MI and promptly activate EMS. Suspicion for MI should be raised in the event of chest pain or discomfort and related symptoms such as palpitations, nausea, vomiting, diaphoresis, and shortness of breath. Research has demonstrated that people with MI who delay seeking assistance and starting therapy usually have less favorable results (39). The American Heart Association reports that 47% of people with acute myocardial infarctions wait more than two hours after symptoms begin to appear before seeking medical attention. This demonstrates how crucial it is to spread knowledge and create awareness of the necessity of quickly identifying and initiating emergency medical help (40).

Immediate interventions

The first care is to minimize symptoms as much as possible, keep the patient stable until more advanced treatment is available, and prevent further cardiac damage. These therapies are often started as soon as emergency medical services (EMS) arrive or continued by emergency hospital professionals.

Administration of aspirin

Unless there are restrictions, aspirin should be given to all suspected instances of MI immediately since it is a vital component of the therapy for acute MI. Aspirin inhibits cyclooxygenase-mediated platelet activation and aggregation, which lowers the risk of thrombus formation and myocardial ischemia (41). As soon as it is feasible, individuals with a suspected MI should be given chewable aspirin (162–325 mg), according to the American College of Cardiology and the American Heart

Association. After that, you should take maintenance medication consistently for the remainder of your life (40).

Use of nitroglycerin for chest pain relief

One typical therapy for MI-related chest discomfort symptoms is nitroglycerin. Since nitroglycerin mainly dilates venous capacitance arteries, which lowers oxygen demand and preload in the heart and lessens angina symptoms, it is categorized as a vasodilator. When treating individuals with suspected MI for chest discomfort, sublingual nitroglycerin is frequently the first medication utilized. Nitroglycerin can induce severe hypotension. Thus, persons who already have hypotension or are using PDE inhibitors at the same time should be cautious (42).

Initiation of cardiopulmonary resuscitation (CPR) if necessary

Cardiopulmonary resuscitation (CPR) must start right away in instances of hemodynamic instability or cardiac arrest to preserve essential organ perfusion and circulation. Before performing advanced life support procedures, competent bystanders or medical professionals should respond right away to administer successful CPR, which consists of chest compressions and rescue breaths. For early defibrillation in patients with ventricular fibrillation or pulseless ventricular tachycardia, an automated external defibrillator (AED) may also be necessary (43).

Advances in Diagnosis and Treatment

High-sensitivity troponin assays for early diagnosis

Identifying myocardial damage at earlier stages of development is essential for preventing heart attacks (myocardial infarctions). This is important because once the muscle tissue has started to die, it is almost impossible to reverse the process. Myocardial infarctions are the leading cause of death among both men and women globally. In contrast to the regular/standard checks for the troponins, which have relatively broad detection levels, high-sensitivity assays use much narrower testing limits, thereby ensuring that we can even pick up a slight rise in troponin amounts sometime in the first few hours after symptoms have set in. (45).

Many studies have shown that high-sensitivity troponin tests are more effective than conventional diagnostic procedures when detecting patients who suffered a heart attack (45). An example is research that appeared in JAMA Cardiology, which indicated that HS assays were more sensitive than their counterparts while having NPVs that allowed safe exclusion of MI. So, because of a faster diagnosis, the patient spent fewer days in the hospital. This means that using this tool helps improve treatment (46). Detecting heart attacks early High-sensitivity troponin testing also improves clinical judgment and allows for better risk assessment in people brought to the hospital with chest pain, hence allowing for immediate commencement of drugs and their appropriate discharging aftercare in place.

Coronary angiography and percutaneous coronary intervention (PCI)

Coronary angiography and percutaneous coronary intervention (PCI) are essential for therapeutic strategies that aim at treating acute myocardial infarction because they allow a conclusive diagnosis and revascularization of occluded coronary arteries. With coronary angiography, myocardial ischemic lesions can be detected, and the architecture of the coronary artery can be visualized. The percutaneous coronary intervention (PCI) is a minimally invasive procedure aimed at unblocking or dilating narrowed or obstructed coronary arteries to restore blood flow into ischemia areas.

Early coronary angiography and percutaneous coronary intervention (PCI) have been proven to be useful for everyone who has had a heart attack, and this is based on numerous research findings (48). When primary PCI is carried out within a few hours of the beginning of symptoms, research published in the New England Journal of Medicine reveals that it is superior to fibrinolytic therapy in terms of lowering mortality, recurrent myocardial infarction, and the need for repeat revascularization. Furthermore, by causing quick and total reperfusion of the infarct-related artery, research like the TIMI (Thrombolysis in Myocardial Infarction) trials have shown how effective PCI is in improving outcomes for patients with ST-segment elevation myocardial infarction (STEMI) (49).

Pharmacological interventions

Antiplatelet agents

Antiplatelet medications are essential to treating MI because they stop platelets from activating and aggregating, preventing thrombus formation and subsequent coronary artery blockage (55). Most often, aspirin, a nonsteroidal anti-inflammatory drug, is used as an antiplatelet agent to treat MI. Thromboxane A2, a powerful platelet activator, is stopped permanently by inhibiting the cyclooxygenase-1 (COX-1) enzyme's activity. Additionally, to lower the risk of stent thrombosis and recurrent ischemic events, patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) are advised to receive dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor such as clopidogrel, ticagrelor, or prasugrel (56).

Antiplatelet treatment has been shown in several cutting-edge studies to be beneficial in lowering adverse cardiovascular events in individuals with MI. For instance, clopidogrel with aspirin decreased the incidence of cardiovascular mortality, myocardial infarction, or stroke in patients with acute coronary syndromes when compared to aspirin alone, according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study (57). Ticagrelor and prasugrel were also more successful than clopidogrel at lowering the frequency of ischemic episodes in patients with acute coronary syndromes in the PLATO and TRITON-TIMI 38 trials (58).

Beta-blockers

The beta-blocker medication family is another commonly used to treat MI. It reduces symptoms, improves left ventricular function, and lowers the heart's oxygen demand. Beta-blockers decrease heart rate, myocardial contractility, and systemic blood pressure by blocking the action of beta-adrenergic receptors. Moreover, beta-blockers antiarrhythmic properties may protect MI patients against ventricular arrhythmias (53).

The use of beta-blockers in the treatment of MI is supported by significant studies like the COMMIT and ISIS-1 investigations, which showed that early beta-blocker medication in patients with acute MI lowered mortality and recurrent myocardial infarction. Despite current guidelines recommending its selective use in hemodynamically stable patients without contraindications such

as heart failure or severe bronchospasm, beta-blocker use in treating MI has changed over time (54).

Statins

Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are lipid-lowering medications that stabilize atherosclerotic plaques and lower low-density lipoprotein cholesterol levels (52). This makes them essential for secondary prevention after MI. Their pleiotropic effects, which improve endothelial function, reduce inflammation, and prevent thrombosis, are the reasons why statins are good for the heart (51).

Two clinical trials that have shown the advantages of statin medication in lowering cardiovascular events and enhancing survival in patients with coronary artery disease, including those who have a history of MI, are the Scandinavian Simvastatin Survival Study (4S) and the PROVE IT-TIMI 22 study. Regardless of baseline cholesterol levels, guidelines from professional associations like the American College of Cardiology and the American Heart Association advise that all patients with acute coronary syndromes start high-intensity statin medication (50).

Emerging therapies and future directions

Recent scientific studies aim to find different ways to treat heart attack patients besides employing traditional medications that may increase their survival chances. Some of the future directions and emerging therapies in MI management include the development of novel antiplatelet agents with improved safety and efficacy profiles, the investigation of adjunctive therapies that target inflammation and stabilize plaque, and the exploration of precision medicine approaches based on genetic profiling and customized risk stratification. Exciting research areas include clinical studies evaluating the efficacy of anti-inflammatory drugs in preventing repeat cardiovascular events and the development of antiplatelet drugs that precisely target platelet activation pathways. By using individual risk prediction algorithms, improvements in precision medicine may refine treatment plans and enable personalized therapies that enhance the long-term prognosis of MI patients.

Conclusion

This thorough study demonstrates the importance of not wasting time getting treatment for myocardial infarction to improve patient outcomes. It is important to note that MI is one of the main causes of death worldwide; therefore, recognizing its symptoms promptly and calling emergency medical services (EMS) is paramount. The word electronic comes from the Greek word "Elektron," meaning amber. Amber is a hard translucent fossil resin used for making jewelry. During the early history of electricity, amber was referred to as electrostatic. Precision medicine holds promise for bettering the treatment of MI by stabilizing plaque and controlling inflammation with cutting-edge methods. All things considered, this all-encompassing method emphasizes the significance of interdisciplinary efforts in strengthening treatment plans and boosting patient outcomes for MI patients.

References

1. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2016, 103:10–8. https://doi.org/10.1136/heartjnl-2016-309530
2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2017, 39:119–77. https://doi.org/10.1093/eurheartj/ehx393
3. Petrov D: Differentiation of aborted myocardial infarction from masquerading myocardial infarction. European Heart Journal. 2006, 27:1885–5. https://doi.org/10.1093/eurheartj/ehl089
4. Jayaraj JC, Davatyan K, Subramanian SS, et al. Epidemiology of Myocardial Infarction. IntechOpen; 2018. https://doi.org/10.5772/intechopen.74768
5. Mendis S. Global progress in prevention of cardiovascular disease. Cardiovascular Diagnosis and Therapy. 2017, 67:S32–8. https://doi.org/10.21037/cdt.2017.03.06
6. Benjamin et al. Correction to: Heart Disease and Stroke Statistics—2018 Update. A Report From the American Heart Association. Circulation. 2018, 137: https://doi.org/10.1161/cir.0000000000000573

7. Frederick G.P. Welt, Simon DI. Atherosclerosis and plaque rupture. Catheterization and cardiovascular interventions. 2001, 53:56–63. https://doi.org/10.1002/ccd.1130
8. Bentzon JF, Falk E. Circulating smooth muscle progenitor cells in atherosclerosis and plaque rupture: Current perspective and methods of analysis. Vascular Pharmacology. 2010, 52:11–20. https://doi.org/10.1016/j.vph.2009.11.005
9. Klein L, Liebson P, Selwyn A. The Molecular and Cellular Basis of Atherosclerosis and Plaque Rupture. Current Cardiology Reviews. 2005, 1:171–9. https://doi.org/10.2174/157340305774574152
10. Brevetti G, Silvestro A, Schiano V, et al. Endothelial Dysfunction and Cardiovascular Risk Prediction in Peripheral Arterial Disease. Circulation. 2003, 108:2093–8. https://doi.org/10.1161/01.cir.0000095273.92468.d9
11. Fangming G, Xiaohuan W, Guangping L, et al. Risk factors of acute myocardial infarction following primary percutaneous coronary intervention among elderly patients. Journal of Geriatric Cardiology. 2009, 67–70. file:///Users/ghazala/Downloads/Risk%20factors%20of%20acute%20myocardial%20infarction%20following%20primary%20percutaneous%20coronary%20intervention%20among%20elderly%20patients.pdf
12. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke statistics—2020 Update. Circulation. 2020, 141: https://doi.org/10.1161/cir.0000000000000757
13. Kivimäki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. The Lancet Public Health. 2017, 2:e277–85. https://doi.org/10.1016/S2468-2667(17)30074-9
14. World Health Organization: Cardiovascular diseases (CVDs). World Health Organization. (2021). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
15. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. ACC Current Journal Review. 2004, 13:15–6. https://doi.org/10.1016/j.accreview.2004.11.072
16. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart

Disease. Journal of the American College of Cardiology. 2012, 60:e44–164. https://doi.org/10.1016/j.jacc.2012.07.013

17. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. European Heart Journal. 2008, 29:932–40. https://doi.org/10.1093/eurheartj/ehn018
18. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004, 110:588–636. https://doi.org/10.1161/01.CIR.0000134791.68010.FA
19. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004, 109:42–6. https://doi.org/10.1161/01.cir.0000108926.04022.0c
20. Han C, Robinson DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. PubMed. 2006, 33:2167–72. https://pubmed.ncbi.nlm.nih.gov/16981296/
21. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2012, 33:1635–701. https://doi.org/10.1093/eurheartj/ehs092
22. Wolf PA. Cigarette Smoking as a Risk Factor for Stroke. JAMA. 1988, 259:1025. https://doi.org/10.1001/jama.1988.03720070025028
23. Whooley MA. Depressive Symptoms, Health Behaviors, and Risk of Cardiovascular Events in Patients With Coronary Heart Disease. JAMA. 2008, 300:2379. https://doi.org/10.1001/jama.2008.711

24. Libby P. Inflammation in atherosclerosis. Nature. 2002, 420:868–74. https://doi.org/10.1038/nature01323
25. Altieri P, Banchs HL, Nieves J. Psoriasis and coronary artery disease: The role of inflammation. Atherosclerosis. 2016, 252:e179. https://doi.org/10.1016/j.atherosclerosis.2016.07.838
26. Folsom A. Hemostatic Risk Factors for Atherothrombotic Disease: An Epidemiologic View. Thrombosis and Haemostasis. 2001, 86:366–73. https://doi.org/10.1055/s-0037-1616234
27. Hiratzka LF, Bakris GL, Beckman JA, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Circulation. 2010, 121: https://doi.org/10.1161/cir.0b013e3181d4739e
28. Fernández-Friera L, Fuster V, López-Melgar B, et al. Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI. Journal of the American College of Cardiology. 2019, 73:1371–82. https://doi.org/10.1016/j.jacc.2018.12.075
29. Goldberg RJ, Gore JM, Gurwitz JH, et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: The Worcester Heart Attack Study. American Heart Journal. 1989, 117:543–9. https://doi.org/10.1016/0002-8703(89)90727-8
30. Canto JG. Prevalence, Clinical Characteristics, and Mortality Among Patients With Myocardial Infarction Presenting Without Chest Pain. JAMA. 2000, 283:3223. https://doi.org/10.1001/jama.283.24.3223
31. Lichtman JH, Leifheit-Limson EC, Watanabe E, et al. Symptom Recognition and Healthcare Experiences of Young Women With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes. 2015, 8:S31–8. https://doi.org/10.1161/circoutcomes.114.001612
32. Milner KA, Funk M, Richards S, et al. Gender differences in symptom presentation associated with coronary heart disease. The American Journal of Cardiology. 1999, 84:396–9. https://doi.org/10.1016/S0002-9149(99)00322-7
33. Wenger NK. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the

2007 Guideline): Highlights for the Clinician. Clinical Cardiology. 2011, 35:3–8. https://doi.org/10.1002/clc.20964

34. Zuidersma M, Ormel J, Conradi HJ, et al. An increase in depressive symptoms after myocardial infarction predicts new cardiac events irrespective of depressive symptoms before myocardial infarction. Psychological Medicine. 2011, 42:683–93. https://doi.org/10.1017/s0033291711001784
35. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018, 138: https://doi.org/10.1161/cir.0000000000000617
36. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of Patients with Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying. Clinical Gastroenterology and Hepatology. 2011, 9:567-576.e4. https://doi.org/10.1016/j.cgh.2011.03.003
37. Kirchberger I, Heier M, Golüke H, et al. Mismatch of presenting symptoms at first and recurrent acute myocardial infarction. From the MONICA/KORA Myocardial Infarction Registry. European Journal of Preventive Cardiology. 2015, 23:377–84. https://doi.org/10.1177/2047487315588071
38. Møller AL, Mills EHA, Gnesin F, et al. Impact of myocardial infarction symptom presentation on emergency response and survival. European Heart Journal Acute Cardiovascular Care. Published Online First: 5 May 2021. https://doi.org/10.1093/ehjacc/zuab023
39. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-elevation Myocardial infarction: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 127:e362-425. https://doi.org/10.1161/CIR.0b013e3182742cf6
40. Rollman JE, Kloner RA, Bosson N, et al. Emergency Medical Services Responses to Out-of-Hospital Cardiac Arrest and Suspected ST-Segment–Elevation Myocardial Infarction During the COVID-19 Pandemic in Los Angeles County. Journal of the American Heart Association. 2021, 10: https://doi.org/10.1161/jaha.120.019635
41. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation. 2013, 127:529–55. https://doi.org/10.1161/cir.0b013e3182742c84

42. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2007, 50:e1–157. https://doi.org/10.1016/j.jacc.2007.02.013
43. Writing Committee for the VISION Study Investigators. Association of Postoperative High-Sensitivity Troponin Levels with Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. *JAMA.* 2017;317(16):1642–1651. doi:10.1001/jama.2017.4360. https://doi.org/10.1001/jama.2017.4360
44. Boeddinghaus J, Twerenbold R, Nestelberger T, et al. Clinical Validation of a Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction. Clinical Chemistry. 2018, 64:1347–60. https://doi.org/10.1373/clinchem.2018.286906
45. Levine G, Patrick C, O'gara T, et al. ACC/AHA FOCUSED UPDATE 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Journal of the American College of Cardiology. 2016, 68: https://doi.org/10.1016/j.jacc.2016.03.513
46. Håkan Geijer, Beckman K-W, Andersson T, et al. Radiation dose optimization in coronary angiography and percutaneous coronary intervention (PCI). I. Experimental studies. European radiology. 2002, 12:2571–81. https://doi.org/10.1007/s00330-001-1237-6
47. Heer T, Hochadel M, Schmidt K, et al. Sex Differences in Percutaneous Coronary Intervention—Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology. Journal of the American Heart Association. 2017, 6: https://doi.org/10.1161/jaha.116.004972
48. Levine G, Patrick C, O'gara T, et al. ACC/AHA FOCUSED UPDATE 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease PCNA/SCAI/STS Guideline for the Diagnosis and Management

of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Journal of the American College of Cardiology. 2016, 68: https://doi.org/10.1016/j.jacc.2016.03.513

49. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 2004, 350:1495–504. https://doi.org/10.1056/nejmoa040583
50. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013, 1: https://doi.org/10.1002/14651858.cd004816.pub5
51. Okazaki S, Yokoyama T, Miyauchi K, Set al. Early Statin Treatment in Patients with Acute Coronary Syndrome. Circulation. 2004, 110:1061–8. https://doi.org/10.1161/01.cir.0000140261.58966.a4
52. Nuttall SL, Langford NJ, Kendall MJ. Beta-blockers in heart failure. 2. Mode of action. Journal of Clinical Pharmacy and Therapeutics. 2001, 26:1–4. https://doi.org/10.1046/j.1365-2710.2001.00316.x
53. Ho PM, Spertus JA, Masoudi FA, et al. Impact of Medication Therapy Discontinuation on Mortality After Myocardial Infarction. Archives of Internal Medicine. 2006, 166:1842–7. https://doi.org/10.1001/archinte.166.17.1842
54. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. Journal of Thrombosis and Haemostasis. 2011, 9:1705–12. https://doi.org/10.1111/j.1538-7836.2011.04432.x
55. Ferguson JJ, Lau TK. New antiplatelet agents for acute coronary syndromes. American Heart Journal. 1998, 135:S194–200. https://doi.org/10.1016/s0002-8703(98)70249-2
56. Cuisset , Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis. 2006, 4:542–9. https://doi.org/10.1111/j.1538-7836.2005.01751.x

57. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial program. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal. 2000, 21:2033–41. https://doi.org/10.1053/euhj.2000.2474